31
Jan
2018
Big Idea, Big Money, Big Skepticism: The Long Run Podcast With Stephane Bancel
Today’s guest on The Long Run is Stephane Bancel. He’s the CEO of Cambridge, Mass.-based Moderna Therapeutics. The company, and the man at the helm, are somewhat controversial. Google Bancel’s name, and the ‘People Also Search For’ window shows famous entrepreneurs like Jeff Bezos, Elon Musk…and Elizabeth Holmes of Theranos infamy. Each situation for those entrepreneurs is different, and comparisons... Read More
30
Jan
2018
State Laws Zero in On Rising Drug Costs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Jan
2018
The Boston Cancer Summit & Seattle Cancer Summit. Two Can’t-Miss Events
Cancer wasn’t that exciting to write about when I started 15 years ago. It is now. Survival rates for several forms of cancer are going in the right direction. Immunotherapy, targeted therapy, new information on genes and proteins that redefine the molecular nature of malignancy? It’s coming together. The science is bursting with creativity, and moving fast. I’m thinking and... Read More
26
Jan
2018
Celgene Pulls the Trigger for Juno, Azar Confirmed, & Half-Hearted Gene Editing
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Jan
2018
Leveraging June’s I-O Team at Penn, Tmunity Fetches $100M from Gilead, Parker & Ping An
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Jan
2018
Lessons in Digging Deep (January Update: Everest Climb to Fight Cancer at Fred Hutch)
Many of you have a big dream. Many of you have your own “Everest” – a big, hairy audacious goal that will take serious time and sacrifice to achieve. I deeply admire those of you doing your best to move the needle for human health, whether it’s for cancer or some other serious illness. When the going gets tough, you... Read More
19
Jan
2018
Celgene’s Rumored Juno Talks, Hospitals Shoot at Generic Drugmakers, & Keytruda Hits a Phase III
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Jan
2018
Reverse Engineering I-O Bispecifics for Autoimmunity, Pandion Snags $58M
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Jan
2018
Getting a Seat at the Table: The Long Run Podcast With Abbie Celniker
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Jan
2018
Celgene Gets a JAK2 for $1.1B, Novo Bids for Ablynx & Pfizer Drops Neuro: Pre#JPM18 Wrap
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Jan
2018
Spark Sets $850K Bar, Microsoft’s Bet on AI for Immune Mapping, & Startup Financings Galore
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Jan
2018
Microsoft Makes Nine-Figure Bet on Adaptive’s TCR-Antigen Map; BioNTech Hauls in $270M for 10-Drug Cancer Pipeline
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Jan
2018
Scholar Rock, After a Year on Pause, Snags $47M to Take New Tack Against SMA
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Jan
2018
Finding a Path in Biotech VC: The Long Run Podcast With Bob More
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
21
Dec
2017
How Did BioMarin Make It? The Long Run Podcast With Daniel Levine & Dan Maher
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Dec
2017
Five Things That I Think I Know About (My) Happiness
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Dec
2017
Walk & Talk With Me on Powell Street at #JPM18
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Dec
2017
A16Z Rakes in New $450M Fund to Build ‘Engineering Biology’ Plays
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Dec
2017
Accelerator, Backed by Corporate VCs, Spreads Wings – But Not in Boston & SF
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Dec
2017
Biotech’s Test: Root for a Tax Windfall Or Support the Next Generation of Scientists?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.